



UNITED STATES PATENT AND TRADEMARK OFFICE

BEST AVAILABLE COPY

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/757,824	01/09/2001	Beverly L. Davidson	875.043US1	8235

21186 7590 02/01/2002

SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A.
P.O. BOX 2938
MINNEAPOLIS, MN 55402

EXAMINER

BANSAL, GEETHA P

ART UNIT	PAPER NUMBER
1642	

DATE MAILED: 02/01/2002

Please find below and/or attached an Office communication concerning this application or proceeding.

BEST AVAILABLE COPY

Office Action Summary

Application No.	09/757824	Applicant(s)	Davidson et al
Examiner	Evelyn Bansal	Group Art Unit	1642

—The MAILING DATE of this communication appears on the cover sheet beneath the correspondence address—

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE -0- MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION. (30 days)

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, such period shall, by default, expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).

Status

- Responsive to communication(s) filed on _____.
- This action is FINAL.
- Since this application is in condition for allowance except for formal matters, **prosecution as to the merits is closed** in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11; 453 O.G. 213.

Disposition of Claims

Claim(s) 1-61 is/are pending in the application.

Of the above claim(s) _____ is/are withdrawn from consideration.

Claim(s) _____ is/are allowed.

Claim(s) _____ is/are rejected.

Claim(s) _____ is/are objected to.

Claim(s) 1-61 are subject to restriction or election requirement.

Application Papers

- See the attached Notice of Draftsperson's Patent Drawing Review, PTO-948.
- The proposed drawing correction, filed on _____ is approved disapproved.
- The drawing(s) filed on _____ is/are objected to by the Examiner.
- The specification is objected to by the Examiner.
- The oath or declaration is objected to by the Examiner.

Priority under 35 U.S.C. § 119 (a)-(d)

- Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d).
- All Some* None of the CERTIFIED copies of the priority documents have been received.
- received in Application No. (Series Code/Serial Number) _____.
- received in this national stage application from the International Bureau (PCT Rule 17.2(a)).

*Certified copies not received: _____

Attachment(s)

- Information Disclosure Statement(s), PTO-1449, Paper No(s). _____
- Interview Summary, PTO-413
- Notice of Reference(s) Cited, PTO-892
- Notice of Informal Patent Application, PTO-152
- Notice of Draftsperson's Patent Drawing Review, PTO-948
- Other LAX Transmittal Sheet

Office Action Summary

BEST AVAILABLE COPY

Application/Control Number: 09/757, 824

Page 2

Art Unit: 1642

DETAILED ACTION

1. Restriction to one of the following inventions is required under 35 U.S.C. 121:
 - I. Claims 1-33, 49-52, drawn to nucleic acid sequence operably linked to a nucleic acid sequence encoding a PTD, classified in class 536, subclass 25.1 and class 435, subclass 69.7.
 - II. Claims 34-48, drawn to a polypeptide operably linked to a nucleic acid sequence encoding a PTD, classified in class 530, subclass 358.
 - III. Claims 53-56, 59, 61, drawn to a method of treating a lysosomal storage disease by administering a polynucleotide, or vector or cell containing the polynucleotide, classified in class 514, subclass 44.
 - IV. Claims 53-54, 57-59, 61, drawn to a method of treating a neurodegenerative disease by administering a polynucleotide, or vector or cell containing the polynucleotide, classified in class 514, subclass 44.
 - V. Claims 60, drawn to a method of treating a genetic disease by administering a polypeptide, classified in class 514, subclass 2.
 - VI. Claims 60, drawn to a method of treating a cancer by administering a polypeptide, classified in class 514, subclass 2.

2. The inventions are distinct, each from the other because of the following reasons:

Inventions I-II are unrelated to each other, and III-VI are unrelated to each other. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together, or they have different modes of operation, or they have different functions, or they have different effects.

(MPEP § 806.04, MPEP § 808.01). In the instant case the different inventions of Groups III-VI are drawn to different methods with different method steps. Each of the methods are patentably distinct since they have different modes of operation and have different functions and effects and measured by different endpoints. Similarly the products of Groups I-II are drawn to different

BEST AVAILABLE COPY

Application/Control Number: 09/757, 824

Page 3

Art Unit: 1642

structurally and chemically distinct products, that have different functions. While it appears that they are related to each other, in fact the products are distinct and independent of each other. Similarly, the products Groups I and II can be used in a number of different distinct and independent methods as shown above.

3. Because these inventions are distinct for the reasons given above and have acquired a separate status in the art as shown by their different classification, their recognized divergent subject matter, and the search required for the different Groups are different, restriction for examination purposes as indicated is proper.

4. Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

5. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a petition under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(I).

6. A dedicated Fax machine is in place to receive your responses. The Fax number is 703-308-4315. A Fax cover sheet is attached to this Office Action for your convenience. Please limit the use of this dedicated Fax number to responses to Written Restrictions.

7. Papers related to this application may be submitted to Group 1640 by facsimile transmission. Papers should be faxed to Group 1640 via the PTO Fax Center located in Crystal Mall 1. The faxing of such papers must conform with the notice published in the Official Gazette, 1096 OG 30 (November 15, 1989). The CM1 Fax Center telephone number is (703) 308-4242 or (703) 305-3014.

BEST AVAILABLE COPY

Application/Control Number: 09/757, 824

Page 4

Art Unit: 1642

8. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Geetha P. Bansal whose telephone number is (703) 305-3955. The examiner can normally be reached on Mondays to Thursdays from 7:00am to 4:30pm and alternate Fridays from 7:00am to 3:30pm. A message may be left on the examiner's voice mail service.

9. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Dr. Anthony Caputa, can be reached on (703) 308-3995.

10. Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the Group receptionist whose telephone number is (703) 308-0196.

January 30, 2002


GEETHA P. BANSAL
PRIMARY EXAMINER